Covid19, Dyspnea
Conditions
Keywords
Dyspnea, Covid19, Cardiopulmonary exercise test
Brief summary
We conducted a national, single center (Hospital Clínico Universitario de Valladolid, Spain, Valladolid), prospective study of patients with prior hospitalization because of COVID-19 who were admitted between March 1st, 2020, and May 15th, 2020. All eligible patients underwent at least at first-time follow-up from the index event. Exclusion criteria were age \< 18 years old, pregnant women, terminally ill patients, active SARS-CoV-2 infections, inability to exercise and previous known severe pulmonary or heart disease. Patients underwent a clinical assessment for symptom burden, questionnaire for quality of life (Kansas City Cardiomyopathy Questionnaire and SF-36), venous blood sampling, 6-minute walking test (6-MWT), tests of lung function (spirometry and diffusing capacity of the lungs for carbon monoxide) and treadmill cardio-pulmonary exercise testing (CPET). 48-hours before the test of lung function and the CPET, all patients yielded a negative result in the reverse transcription-polymerase chain reaction (RT-PCR) for SARS-CoV-2. For definitive analysis patients were assigned to the control group if they did not refer dyspnea at the time of the follow-up, a small asymptomatic out-patient control group without prior hospitalization was also included.
Interventions
DIAGNOSTIC_TESTCardiopulmonary exercise test
Only diagnostic tests
Sponsors
Hospital Clínico Universitario de Valladolid
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Signed Informed Consent * Previous COVID-19 hospitalization with successful discharged * Availability of at least one follow up per clinical protocol
Exclusion criteria
* pregnant women * terminally ill patients * active SARS-CoV-2 infections * inability to exercise * previous known severe pulmonary or heart disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Aerobic capacity | 6 months | Measured as peak oxygen uptake |
| Total Lung Capacity (TLC) | 6 months | Pulmonary function test |
| Force Expiratory Volume in 1 second (FEV1) | 6 months | Pulmonary function test |
| Difussing Lung Capacity of CO (DLCO) | 6 months | Pulmonary function test |
| Forced Vital Capacity (FVC) | 6 months | Pulmonary function test |
| Left Ventricular (LV) Function | 6 months | Left Ventricular (LV) Function (Ecocardiagraphy-measured Cardiac Function) |
| Right Ventricular (RV) Function | 6 months | Right Ventricular (RV) Function (Ecocardiagraphy-measured Cardiac Function) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| interleukine-6 | 6 months | Inflammatory and Cardiac Marker |
| Short Form 36 Health Survey (SF-36) | 6 months | Quality of Life test |
| C reactive protein (CRP) | 6 months | Inflammatory and Cardiac Marker |
| Kansas City Cardiomyopathy Questionnaire (KCCQ) | 6 Months | Quality of Life test |
| 6 Minute Walk Test | 6 months | Walking capacity |
| N-terminal pro hormone B-type natriuretic peptide (NT-proBNP) | 6 months | Inflammatory and Cardiac Marker |
| Troponin-T | 6 months | Inflammatory and Cardiac Marker |
| Ferritin | 6 months | Inflammatory and Cardiac Marker |
| D-Dimer | 6 months | Inflammatory and Cardiac Marker |
Countries
Spain
Outcome results
None listed